Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Activated Haploidentical NK Cells in Recurrent Glioblastoma
NCT05108012Phase 1Unknown
- Sponsor
- Royan Institute
- Start
- Aug 2021
- Primary completion
- Nov 2021
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of haploidentical natural killer cells in glioblastoma (GBM), sponsored by Royan Institute. Primary endpoints: Toxicity assay at 4 weeks, Adverse Events (AEs) at 1 year and 2 more. Status: unknown.
02
Drugs
haploidentical natural killer cells
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05108012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05108012.